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Introduction

Methods

Results

Results

Conclusion

Preliminary data was collected from 101 cases of cervical cancer. Of the
101 cases reviewed, 29 (28.7%) had HPV testing performed within 6
months of their primary cervical cancer diagnosis. Twenty-two (75.9%)
had a positive HPV test and 7 (24.1%) had a negative HPV test. The most
common HPV test modality was Roche Cobas (n=14).

One quarter of our cervical cancers are HPV-negative,
which is higher than the previously reported 5-10%.[4]
Furthermore, we note a trend in our preliminary data set
concerning a more advanced stage presentation with
HPV-negative cancer. While consistent with past
literature, collecting more data about the specific features
of these late-stage cancers may offer some explanation
for this phenomenon. Contemporary HPV based
screening practices might be missing aggressive cervical
cancers and may need to be re-evaluated.

• Cervical cancer is one of the most common gynecologic
cancers in the world and is the second leading cause of
cancer death in women between the ages of 20 to 39,
killing over 4,000 people in the United States in 2020. [1,2]
• The association between human papillomavirus (HPV)
and cervical malignancy is well-documented and
understood, which has led to tremendous pharmaceutical
and public health advancements.
• While historically all cervical cancer was believed to be
secondary to HPV infection, the consensus among
researchers today is that cervical malignancies can exist
independent of HPV.
• Although often pathologically distinct from the classical
HPV-positive type, HPV-negative cervical cancer remains
less understood and is associated with poorer prognoses.[3]

Methods
• A retrospective chart review of patients treated for cervical
cancer at University Medical Center between January 1,
2015 and December 31, 2020 was conducted.
• HPV status was determined by HPV testing within 6
months of histologic diagnosis. HPV-CC was defined as a
negative HPV test and HPV+CC was defined as a positive
HPV test.
• Demographic, clinical, and cancer diagnosis and treatment
details were recorded. Categorical variables were
summarized with HPV groups by reporting counts and
percentages, while continuous variables were summarized
by reporting means and standard deviations.
• Fisher exact tests were used to compare categorical
variable distributions across HPV groups, while WilcoxonRank Sum tests were used to compare continuous
variables. P-values <0.05 were considered statistically
significant. All analyses were conducted in R statistical
software version 4.0.2.

HPV subtypes were not specified for 7 patients, but notable for HPV 16
(n=9), non-16/18 high risk (n=9), HPV 18 (n=6), and HPV45 (n=1). Of
the 29 patients with HPV test results within 6 months of diagnosis, 10
(34.5%) were stage I, 12 (41.4%) stage II, 3 (10.3%) stage III, 2 (6.9%)
stage IV, and 2 (6.9%) stage unknown. Twenty-two (75.8%) were
squamous cell carcinoma, 5 (17.2%) were adenocarcinoma, and 2 (6.9%)
were other histology. Most (81.8%) of stage I-II cases were HPV+CC,
while only 40.0% of Stage III-IV cases were HPV+CC (p = 0.091).

Although no significant trends have been noted among
patient demographics, comparing lifestyle factors and
medical histories of HPV-positive and HPV-negative
patients may yet provide insight into risk factors for
cervical cancer and if or how they differ among the two
pathologies. The American Cancer Society reports that
Louisiana has one of the highest incidence rates of
cervical cancer in the country.[2] Therefore, describing the
prevalence and clinicopathologic features of HPV
negative cervical cancer at large and locally will be vital
to ensuring that our screening and treatment practices
match the needs of the women in our community.
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